ProBio Opens Flagship U.S. Plasmid & Viral Vector Manufacturing Facility in Hopewell, New Jersey to Advance Cell and Gene Therapy
HOPEWELL, N.J., June 27, 2025 /PRNewswire/ — ProBio, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, today announced the opening of its flagship Cell and Gene Therapy Center of Excellence at the Princeton West Innovation Campus in Hopewell, New Jersey. The 128,000 sq ft GMP facility is purpose-built for manufacturing high-quality plasmid DNA and viral vectors, including adeno-associated virus (AAV) and lentiviral vector (LVV) platforms, reflecting ProBio's dedication to accelerating the delivery of transformative medicines.
The celebration included an open house event featuring a guided site tour, ribbon-cutting ceremony, and a keynote address by Donavon Decker, the first person in the world to receive gene therapy for any form of muscular dystrophy in 1999. Decker shared his experience from that landmark trial at Ohio State University—led by Dr. Jerry Mendell—and spoke movingly about how state-of-the-art facilities like ProBio's Hopewell site help translate scientific advances into real patient outcomes.
The ribbon-cutting ceremony featured remarks from prominent leaders: Debbie Hart, CEO of BioNJ; Courtney Peters–Manning, Mayor of Hopewell Township; John Coelho of the New Jersey Economic Development Authority (NJEDA); Michael Vreeland, Site Head of ProBio Hopewell; Allen Guo, CEO of ProBio; and Frank Zhang, Founder of GenScript and Chairman of Legend Biotech.
Mayor Courtney Peters-Manning welcomed the company warmly, stating: 'Hopewell Township is a wonderful place to live and work, and we are thrilled to welcome ProBio to our community, where they will make cutting-edge, life-changing therapies, in addition to creating high-skilled jobs.'
John Coelho of NJEDA emphasized the strategic significance of the opening: 'The opening of ProBio, a state-of-the-art fully integrated end-to-end Contract Development and Manufacturing Organization, will be a significant enhancement to the cell and gene biologics development and biomanufacturing ecosystem, anchoring New Jersey as a leader in the field. The potential to support production for global clinical trial registrations and close proximity to leading precision medical centers will enable faster access of breakthrough medicines to patients.'
Built to meet the most rigorous GMP standards, the Hopewell site is equipped to support clinical-stage development, process-development and scale-up for cell and gene therapy programs. This capability solidifies New Jersey's position as a leader in biopharmaceutical manufacturing. During the open house, guests toured advanced GMP suites and production lines, and engaged with ProBio's scientific and operations teams as well as industry, academic, and government partners.
'This is not just a new facility. It is a beacon of hope for patients waiting for cures,' said Allen Guo, CEO of ProBio. 'Opening the Hopewell center is a milestone in ProBio's global expansion and underscores our mission to support biopharma innovators with high-quality, responsive manufacturing solutions.'
Bringing over 110 high-skilled jobs to New Jersey, ProBio's Hopewell facility continues to expand its capabilities. GMP AAV manufacturing is set to launch by Q3 2025, with GMP LVV services to follow in Q1 2026—enabling support for a broader range of therapeutic candidates from early proof-of-concept through clinical readiness, all within one integrated site.
Located in the heart of New Jersey's rapidly expanding innovation corridor, ProBio's Hopewell facility serves as the company's North American hub, designed to support and complement its broader operations across North America and Europe. This strategic investment aligns with efforts to strengthen transatlantic biomanufacturing capacity and resilience—positioning the site to meet growing demand for advanced therapeutic production across both continents.
For more information about ProBio and its full suite of development and manufacturing services, please visit www.probiocdmo.com.
ABOUT PROBIO ProBio is a global leader in advancing the development and manufacturing of next generation biologics and advanced therapies for the biotech and pharmaceutical industries. As a fully integrated end-to-end Contract Development and Manufacturing Organization (CDMO), ProBio partners with its clients to optimize drug development, accelerate time-to-market, and provide comprehensive life-cycle support.
Through a collaborative, risk-sharing approach, ProBio offers flexible licensing and co-development options for new therapeutics, enabling partners to effectively navigate the complexities of human disease with adaptable, cutting-edge therapeutic approaches.
To learn more about ProBio services, please visit https://www.probiocdmo.com/.
CUSTOMIZED CDMO SOLUTIONS. DEVELOPED FASTER. DELIVERED BETTER.
Media Contact:Alvin Jogasuria Head of Marketing, Americas and Europe[email protected]
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
a day ago
- Malaysian Reserve
ProBio Opens Flagship U.S. Plasmid & Viral Vector Manufacturing Facility in Hopewell, New Jersey to Advance Cell and Gene Therapy
HOPEWELL, N.J., June 27, 2025 /PRNewswire/ — ProBio, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, today announced the opening of its flagship Cell and Gene Therapy Center of Excellence at the Princeton West Innovation Campus in Hopewell, New Jersey. The 128,000 sq ft GMP facility is purpose-built for manufacturing high-quality plasmid DNA and viral vectors, including adeno-associated virus (AAV) and lentiviral vector (LVV) platforms, reflecting ProBio's dedication to accelerating the delivery of transformative medicines. The celebration included an open house event featuring a guided site tour, ribbon-cutting ceremony, and a keynote address by Donavon Decker, the first person in the world to receive gene therapy for any form of muscular dystrophy in 1999. Decker shared his experience from that landmark trial at Ohio State University—led by Dr. Jerry Mendell—and spoke movingly about how state-of-the-art facilities like ProBio's Hopewell site help translate scientific advances into real patient outcomes. The ribbon-cutting ceremony featured remarks from prominent leaders: Debbie Hart, CEO of BioNJ; Courtney Peters–Manning, Mayor of Hopewell Township; John Coelho of the New Jersey Economic Development Authority (NJEDA); Michael Vreeland, Site Head of ProBio Hopewell; Allen Guo, CEO of ProBio; and Frank Zhang, Founder of GenScript and Chairman of Legend Biotech. Mayor Courtney Peters-Manning welcomed the company warmly, stating: 'Hopewell Township is a wonderful place to live and work, and we are thrilled to welcome ProBio to our community, where they will make cutting-edge, life-changing therapies, in addition to creating high-skilled jobs.' John Coelho of NJEDA emphasized the strategic significance of the opening: 'The opening of ProBio, a state-of-the-art fully integrated end-to-end Contract Development and Manufacturing Organization, will be a significant enhancement to the cell and gene biologics development and biomanufacturing ecosystem, anchoring New Jersey as a leader in the field. The potential to support production for global clinical trial registrations and close proximity to leading precision medical centers will enable faster access of breakthrough medicines to patients.' Built to meet the most rigorous GMP standards, the Hopewell site is equipped to support clinical-stage development, process-development and scale-up for cell and gene therapy programs. This capability solidifies New Jersey's position as a leader in biopharmaceutical manufacturing. During the open house, guests toured advanced GMP suites and production lines, and engaged with ProBio's scientific and operations teams as well as industry, academic, and government partners. 'This is not just a new facility. It is a beacon of hope for patients waiting for cures,' said Allen Guo, CEO of ProBio. 'Opening the Hopewell center is a milestone in ProBio's global expansion and underscores our mission to support biopharma innovators with high-quality, responsive manufacturing solutions.' Bringing over 110 high-skilled jobs to New Jersey, ProBio's Hopewell facility continues to expand its capabilities. GMP AAV manufacturing is set to launch by Q3 2025, with GMP LVV services to follow in Q1 2026—enabling support for a broader range of therapeutic candidates from early proof-of-concept through clinical readiness, all within one integrated site. Located in the heart of New Jersey's rapidly expanding innovation corridor, ProBio's Hopewell facility serves as the company's North American hub, designed to support and complement its broader operations across North America and Europe. This strategic investment aligns with efforts to strengthen transatlantic biomanufacturing capacity and resilience—positioning the site to meet growing demand for advanced therapeutic production across both continents. For more information about ProBio and its full suite of development and manufacturing services, please visit ABOUT PROBIO ProBio is a global leader in advancing the development and manufacturing of next generation biologics and advanced therapies for the biotech and pharmaceutical industries. As a fully integrated end-to-end Contract Development and Manufacturing Organization (CDMO), ProBio partners with its clients to optimize drug development, accelerate time-to-market, and provide comprehensive life-cycle support. Through a collaborative, risk-sharing approach, ProBio offers flexible licensing and co-development options for new therapeutics, enabling partners to effectively navigate the complexities of human disease with adaptable, cutting-edge therapeutic approaches. To learn more about ProBio services, please visit CUSTOMIZED CDMO SOLUTIONS. DEVELOPED FASTER. DELIVERED BETTER. Media Contact:Alvin Jogasuria Head of Marketing, Americas and Europe[email protected]
Barnama
2 days ago
- Barnama
Minerva Biotechnologies Unveils Breakthrough To Enhance Stem Cell Treatments
KUALA LUMPUR, June 26 (Bernama) -- Minerva Biotechnologies has published a study in the journal PLOS ONE detailing findings that could resolve long-standing debates in the scientific community regarding the role of the Wnt/β-catenin pathway in human stem cell differentiation and pluripotency. The study, titled 'The Wnt pathway induces a naïve-like subpopulation in primed stem cells, while NME7AB leads to a homogeneous naïve-like population', offers new insights into how stem cell states can be more effectively manipulated for therapeutic applications. 'These data represent a major breakthrough for the large-scale, GMP-compliant manufacture of patient-derived MSCs for therapeutic uses. 'This approach will replace the current practice of sourcing MSCs from bone marrow donors, whose profiles are often unknown or unverified,' said its Chief Executive Officer, Dr Cynthia Bamdad in a statement. Minerva researchers found that activation of the Wnt/β-catenin pathway, in the absence of other growth factors, created two distinct cell populations—naïve OCT4+ XaXa cells surrounded by differentiating OCT4- XaXi cells. While activation of the β-catenin pathway prior to or during differentiation enhanced outcomes for primed stem cells, it did not affect NME7AB-induced naïve state stem cells. The study also found that homogeneous populations of naïve stem cells induced by recombinant NME7AB demonstrated superior differentiation potential compared to their primed counterparts. Notably, induced pluripotent stem cells (iPSCs) generated and expanded in Good Manufacturing Practices (GMP)-compliant minimal media using NME7AB as the sole growth factor differentiated efficiently into mesenchymal stem cells (MSCs). Minerva's resulting MSCs resisted senescence and showed the ability to differentiate into highly pure populations of chondrocytes, osteoblasts and adipocytes—cell types crucial for the repair or regeneration of cartilage, bone and fat tissues.
New Straits Times
5 days ago
- New Straits Times
FRIM empowers local herbal entrepreneurs through HTC
KUALA LUMPUR: The Forest Research Institute Malaysia (FRIM) is committed to empowering and assisting small and medium entrepreneurs to seize opportunities in the herbal industry, which is expected to have a global market reach of RM1.6 trillion by 2030. FRIM said this included support services offered at its Herbal Technology Centre (HTC), which was established in 2005 and had received the Good Manufacturing Practice (GMP) certification. It added that HTC is capable of providing contract manufacturing services to herbal entrepreneurs, and has been recognised as a BioNexus Partner laboratory by BioEconomy Corporation and a National Pharmacy Regulatory Division (NPRA) Manufacturing Licence holder since 2011, and is now a major reference centre in the industry. "HTC has also obtained various certifications, including the GMP for Food (MS 1480:2020), Hazard Analysis Critical Control Point (HACCP)(MS 1514:2009), TQCSI HACCP Code: 2022 as well as the halal certification from the Department of Islamic Development Malaysia for pharmaceutical contract manufacturing. "The main strengths of HTC include its integrity as a government agency capable of safeguarding the intellectual property rights of customers, well-equipped facilities, strategic positioning, value-added services in terms of technical advisory services and research and development," FRIM said in a statement yesterday. FRIM said that since 2016, HTC has provided 2,048 types of services to over 500 clients, in addition to generating income of over RM2.56 million for FRIM. "During that period, a total of 30 herbal products were also registered with NPRA, while over 223,000 units of registered products were released to the market, with the overall value estimated at over RM19 million, thus proving the crucial role played by FRIM in assisting the economic growth of local entrepreneurs," it said. FRIM director-general Datuk Dr Ismail Parlan was quoted as saying that this effort would be continued to ensure more herbal entrepreneurs can produce quality, safe and competitive products for the domestic and international markets. "With increased demand for herbal-based products and awareness of consumers regarding healthy lifestyles, FRIM, through HTC, is ready to play a strategic role in developing the country's herbal industry in a sustainable and high-impact manner," he said. According to FRIM, the market for natural products in Malaysia was estimated to be valued at over RM5 billion in 2023, and it is expected to continue to grow. "The high demand for plant-based products, including health supplements, functional food and traditional medicines, encourages many local entrepreneurs to produce their own products. However, various constraints in terms of legal compliance and the high cost of building GMP-status facilities become a challenge," it said. FRIM added that, based on the Control of Drugs and Cosmetics Regulations 1984, all herbal products with health claims in Malaysia must be registered with NPRA and the Ministry of Health (MOH) to ensure safety and quality. "Unregistered products can be a danger to consumers, as proven by the seizure of more than 70,000 illegal traditional and cosmetic products worth RM10.1 million by the MOH in November 2024," it said. – BERNAMA
